Your session is about to expire
← Back to Search
Maplirpacept + Standard Therapies for Blood Cancers (TTI-622-01 Trial)
TTI-622-01 Trial Summary
This trial is testing an experimental medicine (TTI-622) to see if it's safe and effective for people with various types of blood cancers. The trial will be conducted in two parts, and participants may only participate in one part.
TTI-622-01 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTTI-622-01 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.TTI-622-01 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't taken any experimental drugs or cancer treatments recently.I have not had major surgery in the last 30 days.My liver is working well.My diagnosis is relapsed or refractory diffuse large B-cell lymphoma.I haven't had a stem cell transplant in the last 3 months or have active graft-vs-host disease, except for mild skin issues.I have recovered from side effects of past cancer treatments to mild or my normal level.My kidneys are working well.I have a new diagnosis of AML without TP53 mutations and am considered elderly or unfit for aggressive treatments.My cancer has spread to my brain or spinal cord.My AML is newly diagnosed and has a TP53 mutation.My multiple myeloma has come back or didn't respond to treatment.I can take care of myself and am up and about more than half of my waking hours.I have available tumor tissue, either fresh or from previous tests.My lymphoma has come back or didn't respond to treatment and I don't need blood transfusions.I have not had radiation therapy in the last 14 days.My blood clotting function is normal.My blood counts are within a healthy range.
- Group 1: Cohort F1, F2 and F3: maplirpacept (PF-07901801) + isatuximab, carfilzomib and dexamethasone
- Group 2: maplirpacept (PF-07901801) Monotherapy
- Group 3: Cohort A: maplirpacept (PF-07901801) + Azacitidine
- Group 4: Cohort B: maplirpacept (PF-07901801) + Azacitidine and Venetoclax
- Group 5: Cohort D1 and D2: maplirpacept (PF-07901801) + an anti-CD20 targeting agent
- Group 6: Cohort E1 and E2: single agent maplirpacept (PF-07901801)
- Group 7: Cohort C1, C2 and C3: maplirpacept (PF-07901801) + Carfilzomib and Dexamethasone
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any available vacancies for subjects participating in this clinical trial?
"According to the clinicaltrials.gov database, this trial is still actively recruiting patients and was initially released on June 7th 2018 with its latest update coming November 9th 2022."
Are there any other investigations that have been undertaken regarding TTI-622?
"TTI-622 was first assessed by the Manitoba Blood & Marrow Transplant Program CancerCare Manitoba in 2002. At this time, 1341 clinical trials related to TTI-622 have been finished while 885 are still running with many of these taking place at Ann Arbor, Michigan."
What purpose does TTI-622 typically serve?
"Primarily prescribed to help manage ophthalmia, sympathetic, TTI-622 has also been known to be effective for complete blood count, induction chemotherapy and branch retinal vein occlusion."
To what extent is this medical experiment being conducted with participants?
"Absolutely, according to clinicaltrials.gov the research study is still open for enrollment. Originally posted on June 7th 2018 and last edited November 9th 2022, this trial requires 476 volunteers across 42 medical sites."
Has the United States Food and Drug Administration sanctioned TTI-622?
"The safety of TTI-622 is given a score of 1 since this initial phase trial has only limited evidence regarding its efficacy and security."
How many North American locations are conducting this clinical trial?
"This clinical research is open for enrolment at the University of Michigan Hospitals in Ann Arbor, Norton Women & Children's Hospital in Louisville and Colorado Blood Cancer Institute situated in Denver. There are also 42 similar sites that can be found across the US."
To what end is this research project oriented?
"According to the trial sponsor, Pfizer, the primary objective of this study is a 30-month examination into adverse events associated with TTI-622. In addition, secondary outcomes including its clearance combined with other treatments and single agent use, t1/2 when used in conjunction with approved anticancer medications or alone, and volume of distribution when mixed with selected therapies will be assessed."
Share this study with friends
Copy Link
Messenger